Published in AIDS on March 01, 1997
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med (2014) 7.64
RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev (2007) 3.13
Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev (2009) 2.28
Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J Clin Invest (1998) 1.70
Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32. J Virol (1998) 1.69
Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long-term nonprogressors. J Clin Invest (1997) 1.46
Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status. Proc Natl Acad Sci U S A (1999) 1.37
Host genes and HIV: the role of the chemokine receptor gene CCR5 and its allele. Emerg Infect Dis (1997) 1.35
Higher macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels from CD8+ T cells are associated with asymptomatic HIV-1 infection. Proc Natl Acad Sci U S A (2000) 1.26
CXCR4 and CCR5 genetic polymorphisms in long-term nonprogressive human immunodeficiency virus infection: lack of association with mutations other than CCR5-Delta32. J Virol (1998) 1.25
Pathogenesis of primary R5 human immunodeficiency virus type 1 clones in SCID-hu mice. J Virol (2000) 1.14
Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5. Hum Gene Ther (2013) 1.14
Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5delta32 allele. J Virol (2006) 1.11
Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote. Virology (2007) 1.09
Expression and function of chemokine receptors on human thymocytes: implications for infection by human immunodeficiency virus type 1. J Virol (2001) 1.05
Definition of the stage of host cell genetic restriction of replication of human immunodeficiency virus type 1 in monocytes and monocyte-derived macrophages by using twins. J Virol (1999) 1.03
CCR2-64I polymorphism is not associated with altered CCR5 expression or coreceptor function. J Virol (1999) 0.96
The second extracellular loop of CCR5 contains the dominant epitopes for highly potent anti-human immunodeficiency virus monoclonal antibodies. Antimicrob Agents Chemother (2007) 0.94
Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic Approaches. Front Immunol (2013) 0.92
Persistence of attenuated HIV-1 rev alleles in an epidemiologically linked cohort of long-term survivors infected with nef-deleted virus. Retrovirology (2007) 0.92
Chemokine receptors and chemokines in HIV infection. J Clin Immunol (1998) 0.91
Expression and functional activity of CXCR-4 and CCR-5 chemokine receptors in human thymocytes. Clin Exp Immunol (2002) 0.90
Natural Immunity to HIV: a delicate balance between strength and control. Clin Dev Immunol (2012) 0.87
RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA? Expert Opin Biol Ther (2010) 0.87
Thirty Years with HIV Infection-Nonprogression Is Still Puzzling: Lessons to Be Learned from Controllers and Long-Term Nonprogressors. AIDS Res Treat (2012) 0.86
Host genetic determinants of HIV pathogenesis: an immunologic perspective. Curr Opin HIV AIDS (2008) 0.84
The CCR5 receptor acts as an alloantigen in CCR5Delta32 homozygous individuals: identification of chemokineand HIV-1-blocking human antibodies. Proc Natl Acad Sci U S A (1998) 0.82
Genotyping of the CCR5 chemokine receptor by isothermal NASBA amplification and differential probe hybridization. Clin Diagn Lab Immunol (1999) 0.80
Impact of NNRTI compared to PI-based highly active antiretroviral therapy on CCR5 receptor expression, beta-chemokines and IL-16 secretion in HIV-1 infection. Clin Exp Immunol (2002) 0.80
Chemokine receptor CCR5 Delta 32 genetic analysis using multiple specimen types and the NucliSens Basic Kit. Clin Diagn Lab Immunol (2001) 0.79
A review of the clinical pharmacology of maraviroc. Introduction. Br J Clin Pharmacol (2008) 0.78
Canadian consensus guidelines for the optimal use of maraviroc in the treatment of HIV-infected adults. Can J Infect Dis Med Microbiol (2010) 0.78
Pharmacogenomic implications of the evolutionary history of infectious diseases in Africa. Pharmacogenomics J (2016) 0.78
Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals. AIDS Res Ther (2017) 0.77
The number of CCR5 expressing CD4+ T lymphocytes is lower in HIV-infected long-term non-progressors with viral control compared to normal progressors: a cross-sectional study. BMC Infect Dis (2014) 0.77
Risk of all-cause mortality in HIV infected patients is associated with clinical, immunologic predictors and the CCR5 Δ32 deletion. PLoS One (2011) 0.77
Risk of HIV Infection and Lethality Are Decreased in CCR5del32 Heterozygotes: Focus Nosocomial Infection Study and Meta-analysis. Acta Naturae (2012) 0.77
Human immunodeficiency virus type 1 disease progression, CCR5 genotype, and specific immune responses. Clin Diagn Lab Immunol (1998) 0.76
Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals. AIDS Res Ther (2017) 0.75
Distribution of CC-chemokine receptor-5-∆32 allele among the tribal and caste population of Vidarbha region of Maharashtra state. Indian J Hum Genet (2013) 0.75
The African diaspora: history, adaptation and health. Curr Opin Genet Dev (2016) 0.75
Binding of HIV-2 envelope glycoprotein to CD8 molecules and related chemokine production. Immunology (1998) 0.75
Pharmacogenetics as a tool to tailor antiretroviral therapy: A review. World J Virol (2015) 0.75
The Distribution of CCR2-64I, SDF1-3'A and MCP1-2518 G/A Genes Polymorphism in a Specific High Risk Group from the Northeastern States West Bengal, and Gorkha Population in India. Indian J Virol (2012) 0.75
Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet (1998) 7.53
The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med (1990) 6.94
HL-A antigens and diabetes mellitus. Lancet (1974) 4.42
HL-A antigens and disease. Statistical and genetical considerations. Tissue Antigens (1974) 4.41
HLA and disease 1982--a survey. Immunol Rev (1983) 3.87
Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet (2000) 3.42
Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol (1995) 3.30
Nomenclature for factors of the HLA system, 2010. Tissue Antigens (2010) 3.22
Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood. JAMA (2001) 2.90
Human immunodeficiency virus type 1 envelope gene structure and diversity in vivo and after cocultivation in vitro. J Virol (1992) 2.88
HL-A and disease associations--a survey. Transplant Rev (1975) 2.87
A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat Genet (1999) 2.85
Mice lacking all conventional MHC class II genes. Proc Natl Acad Sci U S A (1999) 2.83
Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. Lancet (1999) 2.80
Dual effect of CCR5 delta 32 gene deletion in HIV-1-infected patients. Copenhagen AIDS Study Group. Lancet (1997) 2.70
Mannose-binding lectin polymorphisms and susceptibility to infection in systemic lupus erythematosus. Arthritis Rheum (1999) 2.66
A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science (1997) 2.58
Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study Group. JAMA (1994) 2.56
The efficacy of inosine pranobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection. The Scandinavian Isoprinosine Study Group. N Engl J Med (1990) 2.46
Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet (1973) 2.41
Improved diagnosis of Pneumocystis carinii infection by polymerase chain reaction on induced sputum and blood. Lancet (1992) 2.40
Typing of methicillin-resistant Staphylococcus aureus isolates from Düsseldorf by six genotypic methods. J Med Microbiol (1998) 2.39
Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood (2001) 2.37
Increased frequency of homozygosity of abnormal mannan-binding-protein alleles in patients with suspected immunodeficiency. Lancet (1995) 2.31
A new frequent allele is the missing link in the structural polymorphism of the human mannan-binding protein. Immunogenetics (1994) 2.31
Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies. J Acquir Immune Defic Syndr (1992) 2.29
Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis (1994) 2.26
Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest (1999) 2.24
A high plasma concentration of TNF-alpha is associated with dementia in centenarians. J Gerontol A Biol Sci Med Sci (1999) 2.24
Effects of sodium restriction on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride: a meta-analysis. JAMA (1998) 2.24
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat (2014) 2.23
Specific information concerning taxonomy, pathogenicity and methicillin resistance of staphylococci obtained by a multiplex PCR. J Med Microbiol (1997) 2.16
Different molecular events result in low protein levels of mannan-binding lectin in populations from southeast Africa and South America. J Immunol (1998) 2.11
HL-A antigens and multiple sclerosis. Lancet (1972) 2.09
Long-term seropositivity for human T-lymphotropic virus type III in homosexual men without the acquired immunodeficiency syndrome: development of immunologic and clinical abnormalities. A longitudinal study. Ann Intern Med (1986) 2.06
Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med (2001) 2.05
[Travelers' diarrhea]. Ugeskr Laeger (1993) 2.03
Infectious liver diseases in three groups of Copenhagen workers: correlation of hepatitis A infection to sewage exposure. Arch Environ Health (1981) 2.03
Coalescent estimates of HIV-1 generation time in vivo. Proc Natl Acad Sci U S A (1999) 2.02
[Cytomegalovirus infection. A review]. Ugeskr Laeger (1993) 2.02
Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. Int J Epidemiol (1997) 1.97
MLC typing in juvenile diabetes mellitus and idiopathic Addison's disease. Transplant Rev (1975) 1.97
Variation in human T lymphotropic virus III (HTLV-III) antibodies in homosexual men: decline before onset of illness related to acquired immune deficiency syndrome (AIDS). Br Med J (Clin Res Ed) (1985) 1.93
Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet (1997) 1.92
Combination of methylprednisolone pulse therapy and remission inducing drugs in rheumatoid arthritis. Ann Rheum Dis (1987) 1.91
Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC. Antimicrob Agents Chemother (1998) 1.91
Nomenclature for factors of the HLA system, 2002. Tissue Antigens (2002) 1.89
Phylogenetic analysis of 48 papillomavirus types and 28 subtypes and variants: a showcase for the molecular evolution of DNA viruses. J Virol (1992) 1.88
Differential distribution of Australia-antigen-associated particles in patients with liver diseases and normal carriers. N Engl J Med (1973) 1.86
Production of selenomethionine-labelled proteins using simplified culture conditions and generally applicable host/vector systems. Appl Microbiol Biotechnol (2001) 1.83
Followup study on patients with Reiter's disease and reactive arthritis, with special reference to HLA-B27. Arthritis Rheum (1982) 1.83
Prediction of O-glycosylation of mammalian proteins: specificity patterns of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase. Biochem J (1995) 1.81
Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. J Infect Dis (1995) 1.79
Increasing frequency of vertebral osteomyelitis following Staphylococcus aureus bacteraemia in Denmark 1980-1990. J Infect (1997) 1.79
Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods (2004) 1.78
HLA genotype distribution and genetic models of insulin-dependent diabetes mellitus. Ann Hum Genet (1981) 1.78
Genetics of HLA disease association. Annu Rev Genet (1981) 1.74
The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals. J Antimicrob Chemother (1998) 1.71
Detection of cytomegalovirus DNA in serum correlates with clinical cytomegalovirus retinitis in AIDS. J Infect Dis (1994) 1.69
Human cell-mediated cytotoxicity against modified target cells is restricted by HLA. Nature (1977) 1.69
Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat (2014) 1.68
Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat (2014) 1.67
Temporal relation of antigenaemia and loss of antibodies to core antigens to development of clinical disease in HIV infection. Br Med J (Clin Res Ed) (1987) 1.65
Studies of the HLA system and insulin-dependent diabetes mellitus. Diabetes Care (1980) 1.63
YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians (1999) 1.62
Association of mannose-binding-lectin deficiency with severe atherosclerosis. Lancet (1998) 1.62
Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J Antimicrob Chemother (1998) 1.61
Ageing, tumour necrosis factor-alpha (TNF-alpha) and atherosclerosis. Clin Exp Immunol (2000) 1.61
Increasing incidence but decreasing in-hospital mortality of adult Staphylococcus aureus bacteraemia between 1981 and 2000. Clin Microbiol Infect (2007) 1.61
Incidence and meaning of persistence of Australia antigen in patients with acute viral hepatitis: development of chronic hepatitis. N Engl J Med (1971) 1.60
Clinical course of primary HIV infection: consequences for subsequent course of infection. BMJ (1989) 1.60
Effect of thapsigargin on cytoplasmic Ca2+ and proliferation of human lymphocytes in relation to AIDS. Biochim Biophys Acta (1988) 1.59
Severe acquired immunodeficiency in European homosexual men. Br Med J (Clin Res Ed) (1982) 1.59
Nosocomial HIV-transmission in an outpatient clinic detected by epidemiological and phylogenetic analyses. AIDS (1999) 1.58